Indeed, pharmacologic blockade of CD44 by anti-CD44 antibody treatment in DIO mice suppressed visceral adipose tissue inflammation compared to controls and decreased fasting plasma glucose level, weight gain, liver steatosis, and insulin resistance to levels equal to or better than those seen in therapies using the anti-diabetic drugs metformin and pioglitazone [95]. This evidence concerns the gene CD44 and Insulin resistance.